title: Influence of IFN-gamma and its receptors in human breast cancer.
abstract: BACKGROUND
  Interferons are a group of proteins that trigger multiple responses including prevention of viral replication, inhibition of cell growth, and modulation of cell differentiation. In different mammary carcinoma cell lines IFNgamma induces growth arrest at mid-G1. At the present there are no in vivo studies in human breast. The aim of this study was to investigate the expression patterns of IFNgamma and its two receptors (IFNgamma-Ralpha and IFNgamma-Rbeta) by Western blot and immunohistochemistry, in order to elucidate its role in the different types of human breast cancer (in situ and infiltrative).
  
  
  METHODS
  Immunohistochemical and semiquantitative study of IFNgamma, its receptors types (IFNgamma-Ralpha and IFNgamma-Rbeta), cell proliferation (proliferating cell nuclear antigen, also named PCNA), and apoptosis (TUNEL method) was carried between the three breast groups (fibrocystic lesions, in situ tumors and infiltrating tumors).
  
  
  RESULTS
  In the three groups of patients, IFNgamma and IFNgamma-Ralpha immunoreactions appeared in the cytoplasm while IFNgamma-Rbeta also was found in the nucleus. The optical density to IFNgamma was higher in in situ carcinoma than in benign and infiltrating tumors. When we observed IFNgamma-Ralpha, the optical density was lower in infiltrating carcinoma than in benign and in situ tumors (the higher density). To IFNgamma-Rbeta, the optical density was similar in the three group samples. In tumor samples PCNA and TUNEL index was significantly higher; than in benign diseases. PCNA index increased with the malignance. No significant differences were found between cancer types to TUNEL. IFNgamma could be a potential therapeutic tool in breast cancer. However, tumor cells are able to escape from the control of this cytokine in the early tumor stages; this is probably due to a decreased expression of IFNgamma, or also to an alteration of either its receptors or some transduction elements.
  
  
  CONCLUSIONS
  We conclude that the decrease in the % positive samples that expressed IFNgamma and IFNgamma-Ralpha together with the nuclear localization of IFNgamma-Rbeta, could be a tumoral cell response, although perhaps insufficient to inhibit the uncontrolled cell proliferation. Perhaps, IFNgamma might be unable to activate p21 to stop the cell cycle, suggesting a possible participation in breast cancer development.
authors: Department of Cell Biology and Genetics, University of Alcalá, E-28871, Alcalá de Henares, Madrid, Spain. ignacio.tunon@uah.es.
authors: Ignacio
authors: I
authors: García-Tuñón
authors: Mónica
authors: M
authors: Ricote
authors: Antonio
authors: A
authors: Ruiz A
authors: Benito
authors: B
authors: Fraile
authors: Ricardo
authors: R
authors: Paniagua
authors: Mar
authors: M
authors: Royuela
mesh_terms: D000328:Adult; D000368:Aged; D015153:Blotting, Western; D001943:Breast Neoplasms / Q000378:metabolism* / Q000473:pathology; D049109:Cell Proliferation; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007371:Interferon-gamma / Q000378:metabolism*; D008875:Middle Aged; D017471:Receptors, Interferon / Q000378:metabolism*; D000096743:Interferon gamma Receptor
chemical_list: D007371:Interferon-gamma; D017471:Receptors, Interferon; D000096743:Interferon gamma Receptor
references: Breast Cancer Res Treat. 1991 Aug;18(3):165-70
references: 1756259
references: Int J Cancer. 1998 Jul 3;77(1):138-45
references: 9639405
references: EMBO J. 1999 Mar 1;18(5):1223-34
references: 10064589
references: Eur J Cancer. 1996 Dec;32A(13):2312-8
references: 9038615
references: Zhonghua Nan Ke Xue. 2005 Jun;11(6):448-51, 454
references: 15999492
references: Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2217-24
references: 15598783
references: Ann Surg. 2001 May;233(5):623-9
references: 11323500
references: Int J Cancer. 1998 May 4;76(3):423-9
references: 9579582
references: Histopathology. 2005 Jul;47(1):82-9
references: 15982327
references: Cancer Res. 2000 Oct 15;60(20):5673-80
references: 11059759
references: Clin Cancer Res. 2005 Oct 15;11(20):7545-53
references: 16243830
references: Eur Cytokine Netw. 2000 Mar;11(1):119-27
references: 10705309
references: J Interferon Cytokine Res. 2001 Nov;21(11):951-9
references: 11747627
references: Cell. 1988 Oct 21;55(2):273-80
references: 2971451
references: Immunity. 1994 Sep;1(6):447-56
references: 7895156
references: Cancer Res. 2003 Oct 1;63(19):6424-31
references: 14559832
references: J Surg Res. 1996 Jul 15;64(1):68-74
references: 8806476
references: Cancer Sci. 2006 Oct;97(10):1044-9
references: 16984377
references: Eur J Cancer Clin Oncol. 1986 Apr;22(4):419-26
references: 3089802
references: Cancer Res. 1990 Jun 15;50(12):3473-86
references: 1692761
references: Cell. 1994 Mar 11;76(5):803-10
references: 8124717
references: Cell Growth Differ. 2000 Jun;11(6):335-42
references: 10910100
references: Br J Cancer. 1993 Aug;68(2):352-6
references: 8347490
references: Cancer Invest. 1995;13(2):165-72
references: 7874570
references: Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1198-205
references: 8108387
references: Cell. 1994 Mar 11;76(5):793-802
references: 8124716
references: Biochem J. 2002 Aug 1;365(Pt 3):825-32
references: 11936954
references: Cancer Lett. 2003 Jun 10;195(2):201-10
references: 12767529
references: Oncogene. 1999 Jun 24;18(25):3725-36
references: 10391680
references: Cancer Invest. 2006 Mar;24(2):119-25
references: 16537179
references: Cell Growth Differ. 1996 Mar;7(3):289-300
references: 8838859
references: Cancer. 1984 Feb 1;53(3 Suppl):783-9
references: 6198060